Trials / Completed
CompletedNCT01609023
A Study of Rituximab (MabThera) in Combination With Chemotherapy in Participants With CD20-Positive B-Cell Chronic Lymphocytic Leukemia
A Non-Interventional, Observational Phase IV Study to Evaluate Safety of Rituximab (Mabthera®) in Combination With Chemotherapy in Patients Treated With CD20+ Β Chronic Lymphocytic Leukemia
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 67 (actual)
- Sponsor
- Hoffmann-La Roche · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This observational study will evaluate the safety and efficacy of rituximab in combination with chemotherapy in first- and second-line treatment of participants with cluster of differentiation 20 (CD20)-positive B-cell chronic lymphocytic leukemia. Data will be collected from eligible participants receiving rituximab according to the Summary of Product Characteristics (SPC) during 6 months of treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rituximab | Rituximab will be administered in combination with chemotherapy according to SPC and routine clinical practice. |
Timeline
- Start date
- 2012-04-01
- Primary completion
- 2015-11-01
- Completion
- 2015-11-01
- First posted
- 2012-05-31
- Last updated
- 2018-06-26
- Results posted
- 2017-06-14
Locations
9 sites across 1 country: Greece
Source: ClinicalTrials.gov record NCT01609023. Inclusion in this directory is not an endorsement.